Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Dermatology
•
Cutaneous Lymphomas
Would you consider using a JAK inhibitor for CTCL?
Related Questions
Would you give adjuvant radiation after complete resection of a small primary cutaneous follicular lymphoma of the scalp?
After achieving clinical response to bexarotene for cutaneous lymphoma (e.g., MF stage Ib or FMF), do you wean to the lowest dose for sustained remission, and if so, when?
In an older patient with pembrolizumab-associated chronic eczematous dermatitis—worsened by dupilumab and with biopsies showing spongiotic dermatitis with atypical lymphocytes, would a trial of a JAK inhibitor be appropriate while monitoring for possible early CTCL?
Do you feel there is any role for neoadjuvant imatinib in pediatric DFSP with the classic translocation given that surgery can introduce high morbidity?
What clinical scenarios warrant the use of a skin substitute?
What treatment options would you recommend for a patient with severe generalized pustular psoriasis who has a history of colon cancer (s/p chemotherapy) and well-controlled HIV?
What treatment combination approach would you recommend for mucous membrane pemphigoid?
Do you offer prophylactic antibiotics or valacyclovir prior to ablative laser therapy?
What additional workup do you pursue in a patient in whom you suspect Yellow Nail Syndrome?
How do you use transexamic acid (TXA) during dermatologic procedures?
